Sialix, Inc is developing products for the treatment and prevention of cancer and chronic inflammatory conditions associated with ingestion of non-human sialic acids which are found in red meat and other dietary sources. The company is advancing two complementary programs: an oncology therapeutic targeting ovarian and other solid tumors, and a prophylactic nutritional supplement to reduce inflammation and the resulting risk of cancer and cardiovascular disease. Sialix has licensed a broad patent portfolio from UCSD and assembled a team of industry veterans and glycobiology experts to support the development of these products.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/30/13 | $1,000,000 | Angel |
Boston Harbor Angels Launchpad Angels Maine Angels Mass Medical Angels | undisclosed |
